Rhode Island 2025 Regular Session

Rhode Island House Bill H5498

Introduced
2/13/25  

Caption

Requires the secretary of the executive office of health and human services to monitor and mandate changes to the price-setting practices of pharmacy benefit managers to prohibit the spread pricing payment model.

Impact

The passage of HB 5498 would significantly alter the legislative framework governing how prescription drugs are priced and reimbursed under Medicaid in Rhode Island. By prohibiting spread pricing, the bill seeks to enhance the financial sustainability of the state's Medicaid program, thus potentially leading to cost savings for both the state and its residents. Additionally, by mandating that processes be established for PBM oversight, the bill would position the Health and Human Services office to play a more active role in regulating drug pricing strategies and ensuring fair reimbursement practices.

Summary

House Bill 5498 aims to protect Rhode Islanders and the state Medicaid program from excessive prescription drug costs by imposing stricter regulations on pharmacy benefit managers (PBMs). The bill distinctly requires greater transparency and accountability from PBMs, primarily focusing on the controversial spread pricing payment model, where PBMs charge health plans more than they reimburse pharmacies. This model not only increases costs for states and patients but also raises ethical concerns regarding the profit motives of PBMs in the healthcare landscape.

Contention

Despite the policymakers' intentions behind HB 5498, the bill has sparked debates regarding its implications on the pharmaceutical industry and its potential effects on drug accessibility. Some stakeholders argue that stringent regulations on PBMs may inadvertently hinder their ability to negotiate better prices for consumers. Additionally, the impact on the market dynamics of drug pricing remains uncertain, as adjustments to the spread pricing practices could lead to retaliation or adjustments by PBMs to maintain their profit margins. Therefore, advocates and opponents of the bill alike recognize that a careful balance must be struck to ensure that the reform does not lead to unintended consequences in the state's healthcare system.

Companion Bills

No companion bills found.

Similar Bills

LA HB2

Provides for Medicaid eligibility determination functions and Medicaid fraud detection and prevention (Items #14 and 15) (EG INCREASE GF EX See Note)

LA HB5

Provides for Medicaid eligibility determination functions and Medicaid fraud detection and prevention (Items #14 and 15)

LA HB480

Provides relative to Medicaid fraud detection and prevention (RE INCREASE GF EX See Note)

LA SB7

Provides relative to Medicaid eligibility determination functions and Medicaid fraud detection and prevention. (Item #14 and Item #15) (gov sig)

LA HB213

Provides for Medicaid eligibility determination functions and Medicaid fraud detection and prevention (EG INCREASE GF EX See Note)

LA HB251

Requires DHH to institute Medicaid cost containment measures to the extent allowed by federal regulations (OR DECREASE GF EX See Note)

LA HB280

Institutes premium payment requirements in the Medicaid program

LA HB4

Makes Medicaid eligibility for certain enrollees contingent upon premium payments (Item #16) (OR INCREASE SG RV See Note)